For the Inventor, By the Inventor

Enter inventor name

Del Mar, CA, United States of America

Mark D Erion

USPTO Granted Patents = 61 (Patent Applications = 4)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 5)

Average Co-Inventor Count = 3.7

ph-index = 19

Forward Citations = 1,815(Granted Patents)

Inventors with similar research interests:

Location History:

Del-Mar, CA (US) (1992 - 1994)
Livingston, NJ (US) (1991 - 1998)
Mountainside, NJ (US) (2017 - 2019)
Del Mar, CA (US) (1996 - 2021)
Brookline, MA (US) (2022 - 2024)

Company Filing History:

Metabasis Therapeutics, Inc.

Viking Therapeutics, Inc.

Biocryst Pharmaceuticals, Inc.

6. 2 out of 6,850

Ciba-geigy Corporation

7. 1 out of 613

Sankyo Company, Limited

Gensia Sicor Inc.

9. 1 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 1991-2025

Loading Chart...

Loading Chart...

Loading Chart...

61 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12440502 - Use of thyroid beta-agonists (2025-10-14),

2. 11951114 - Use of thyroid beta-agonists (2024-04-09),

3. 11351183 - Use of thyroid beta-agonists (2022-06-07),

4. 10925885 - Thyromimetics for the treatment of fatty liver diseases (2021-02-23),

5. 10709718 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2020-07-14),

6. 10420781 - Thyroid hormone receptor agonist and use thereof (2019-09-24),

7. 10174062 - Activators of glucokinase (2019-01-08),

8. 10130643 - Thyromimetics for the treatment of fatty liver diseases (2018-11-20),

9. 10034891 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2018-07-31),

10. 9809545 - Factor XIa inhibitors (2017-11-07),

11. 9522926 - Activators of glucokinase (2016-12-20),

12. 9340566 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2016-05-17),

13. 8962618 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof (2015-02-24),

14. 8940927 - Activators of glucokinase (2015-01-27),

15. 8664195 - Phosphorus-containing prodrugs (2014-03-04),

Title: The Innovative Journey of Mark D. Erion

Introduction: Mark D. Erion, based in Del Mar, California, is a renowned inventor with an impressive portfolio of 58 patents. His contributions to the field of medicine, particularly in the treatment of complex disorders, have garnered attention and respect in the scientific community.

Latest Patents: Among his latest inventions, Dr. Erion has developed innovative methods utilizing thyroid beta-agonists, specifically aimed at treating X-linked adrenoleukodystrophy. His commitment to advancing medical science is evident through these cutting-edge solutions that address critical health issues.

Career Highlights: Dr. Erion has held significant positions at leading biopharmaceutical companies, including Metabasis Therapeutics, Inc. and Gensia, Inc. His work in these organizations has been pivotal in pushing the boundaries of therapeutic development and patient care.

Collaborations: Throughout his illustrious career, Dr. Erion has collaborated with notable professionals, including K Raja Reddy and Serge H. Boyer. These partnerships have facilitated the exchange of innovative ideas and enhanced research efforts in their respective fields.

Conclusion: Mark D. Erion's extensive contributions to patenting, especially in therapeutic methods, signify his role as a key innovator in medicine. His dedication to improving healthcare solutions through his inventions will undoubtedly continue to inspire future advancements in the industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…